OR4F6 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Calcium channel blocker that inhibits calcium influx through L-type calcium channels. OR4F6 is a G protein-coupled receptor potentially linked to calcium signaling; thus, nifedipine could decrease OR4F6-mediated signaling by reducing available intracellular calcium. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibitor of ROCK (Rho-associated protein kinase), which plays a role in actin cytoskeleton organization. Since GPCR signaling including OR4F6 can involve cytoskeletal changes for receptor internalization and signaling, Y-27632 could indirectly inhibit OR4F6 by stabilizing the actin cytoskeleton and inhibiting receptor internalization. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Inhibits Gi/o type G proteins by ADP-ribosylation. OR4F6, as a GPCR, may signal through Gi/o proteins, and pertussis toxin could inhibit this signaling pathway, leading to decreased OR4F6 function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylyl cyclase, increasing cAMP levels and activating PKA. This can lead to phosphorylation and desensitization of GPCRs like OR4F6, leading to decreased receptor activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Non-selective beta-adrenergic receptor antagonist that may block GPCRs like OR4F6 if they share similar signaling pathways. This could indirectly prevent OR4F6 activation. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
PPARγ antagonist, which may influence GPCR function by affecting transcriptional regulation of signaling components. As a result, GW9662 could indirectly reduce OR4F6 functionality by altering its signaling environment. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $47.00 $105.00 $322.00 | 45 | |
Inhibits nitric oxide synthase, potentially affecting cyclic GMP levels and thus GPCR signaling. As OR4F6 may be influenced by nitric oxide pathways, L-NAME could indirectly inhibit OR4F6 signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, which could impede MAPK/ERK pathway activation downstream of GPCR signaling. Since OR4F6 is a GPCR, PD98059 could diminish OR4F6-mediated responses by inhibiting this pathway. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Antipsychotic that antagonizes various GPCRs, and could block OR4F6 if it shares allosteric modulation or downstream signaling components, leading to reduced OR4F6 activity. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $97.00 $144.00 $648.00 | 47 | |
PKA inhibitor that can prevent phosphorylation events downstream of GPCRs like OR4F6, potentially leading to a reduction in OR4F6 signaling capacity. | ||||||